XML 19 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Other Receivables	3 Months Ended
	Mar. 31, 2024
Other Receivables, Net, Current [Abstract]
Other Receivables	6. Other Receivables Contemporaneous with the Company’s New Drug Application, or NDA, submission to the U.S. Food and Drug Administration for revumenib, it was required to pay a $6.1 million refundable fee under the Prescription Drug User Fee Act, or PDUFA. The $6.1 million payment was made in January 2024.

X

- Definition

Other Receivables [Text Block]

+ References

No definition available.

+ Details

Name:	sndx_OtherReceivablesTextBlock
Namespace Prefix:	sndx_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_OtherReceivablesNetCurrentAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration